Dynavax Technologies reported $60.09M in Cost of Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
TG Therapeutics TGTX:US 292K 144K
Abbvie ABBV:US $ 4341M 157M
Adma Biologics ADMA:US $ 20.3M 1.46M
Agenus AGEN:US $ 817K 150K
Alexion Pharmaceuticals ALXN:US $ 125.4M 26.8M
Amgen AMGN:US $ 1609M 28M
Astrazeneca AZN:US 3.82B 1.63B
AstraZeneca AZN:LN 3824M 1631M
Biogen BIIB:US $ 511.8M 52.1M
Biomarin Pharmaceutical BMRN:US $ 103.54M 23.52M
Bristol Myers Squibb BMY:US $ 2291M 160M
Dynavax Technologies DVAX:US $ 60.09M 45.24M
Gilead Sciences GILD:US $ 1223M 167M
Glaxosmithkline GSK:US $ 2822M 303M
Gw Pharmaceuticals GWPH:US $ 11.81M 1.39M
Merk MRK:US $ 3056M 14M
Nektar Therapeutics NKTR:US $ 5.31M 2.36M
Neurocrine Biosciences NBIX:US $ 4.2M 1.1M
Novartis NOVN:VX SF 3848M 94M
Pfizer PFE:US $ 9931M 2939M
Regeneron Pharmaceuticals REGN:US $ 453.2M 240.5M
Sarepta Therapeutics SRPT:US $ 23.44M 3.93M
Vertex Pharmaceuticals VRTX:US $ 236.51M 8.54M